It was great presenting some of our group’s work on dermatofibrosarcoma protuberans at the AACR meeting in Philadelphia. Find out here how we’ve identified CDK4 as a therapeutic target in imatinib-resistant DFSP, while establishing a novel laboratory model for this rare cutaneous sarcoma.
